Although a clinical trial in Botswana initially showed a link between periconceptional exposure to dolutegravir and a small increase in infant neural tube defects, the apparent increase was not present after further study, and it is unknown whether this increase was truly due to dolutegravir or to another factor, such as folate deficiency.